Retrospective evaluation of gabapentin for cancer-related neuropathic pain
10.2512/jspm.5.219
- VernacularTitle:神経障害性がん疼痛に対するガバペンチンの使用状況とその評価
- Author:
Mika Baba
;
Ikuo Gomyo
- Publication Type:Journal Article
- Keywords:
gabapentin;
cancer pain;
neuropathic pain;
palliative care
- From:Palliative Care Research
2010;5(2):219-226
- CountryJapan
- Language:Japanese
-
Abstract:
Purpose: The purpose of this investigation was to evaluate a suite of factors that may influence the use of gabapentin for the treatment of cancer pain in our hospital. Methods: We carried out a retrospective investigation of 52 patients hospitalized in our department with cancer-related neuropathic pain and under gabapentin treatment. Patients were divided into two groups: high dose (≥1,800mg gabapentin daily) and low dose (≤1,600mg gabapentin daily). The two groups were compared in terms of a suite of factors including patient background, type of neuropathic pain, dose of adjuvant analgesic drugs, period of administration, and the incidence of adverse effects. Results: Of the total number of patients involved in the study, 52% were in the high dose group. Patient age was significantly lower in the high dose group. There were no significant differences between the two groups in the dose of opioid analgesics, the number of adjuvant analgesic drugs, or the duration of administration. The incidence of adverse effects did not increase in the high dose group. Conclusion: In this retrospective investigation, we conclude that approximately half of our patient study population with cancer-related neuropathic pain may require daily gabapentin dose of 1,800mg or more. In addition, we observed that larger doses of opioid analgesics were used in the high dose group but without risk of increased adverse effects. This phenomenon may have been influenced by the lower patient age in the high dose group. Palliat Care Res 2010; 5(2): 219-226
